PSA affects prostate cancer cell invasion in vitro and induces an osteoblastic phenotype in bone in vivo

Prostate Cancer and Prostatic Diseases

Volumn 14, Issue 4, 2011, Pages 286-294

  Cumming, A P ^a   Hopmans, S N ^b   Vukmirovic Popovic S ^c   Duivenvoorden, W C ^a,b  

^a LAKEHEAD UNIVERSITY   (Canada)

^b JURAVINSKI CANCER CENTRE   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

bone metastasis; invasion; kallikrein; PSA

Indexed keywords

DNA; PROSTATE SPECIFIC ANTIGEN; PROTEIN PRECURSOR; SERINE PROTEINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; BONE METASTASIS; CANCER INVASION; CELL CLONING; CELL MIGRATION; CELL STRAIN; CELL STRAIN DU 145; CELL STRAIN MATLYLU; CONTROLLED STUDY; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OSTEOBLAST; PHENOTYPE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROTEIN SECRETION; STEREOLOGY; WESTERN BLOTTING;

ANIMALS; BONE AND BONES; CELL LINE, TUMOR; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; OSTEOBLASTS; PHENOTYPE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RATS; TRANSFECTION;

EID: 80955163794     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2011.34     Document Type: Article

References (38)

1. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L et al. SEER Cancer Statistics Review, 1975-2002. National Cancer Institute: Bethesda, MD, 2004. http://seer.cancer.gov/csr/1975-2002.
2. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002; 99: 157-166. (Pubitemid 34309470)
3. Webber MM, Waghray A, Bello D. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res 1995; 1: 1089-1094.
4. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985; 76: 1899-1903. (Pubitemid 16196061)
5. Malm J, Hellman J, Hogg P, Lilja H. Enzymatic action of prostate-specific antigen (PSA or hK3): substrate specificity and regulation by Zn(2+), a tight-binding inhibitor. Prostate 2000; 45: 132-139.
6. Robert M, Gagnon C. Semenogelin I: a coagulum forming, multifunctional seminal vesicle protein. Cell Mol Life Sci 1999; 55: 944-960. (Pubitemid 29304448)
7. Gjertson CK, Albertsen PC. Use and assessment of PSA in prostate cancer. Med Clin North Am 2010; 95: 191-200.
8. Lövgren J, Rajakoski K, Karp M, Lundwall A, Lilja H. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun 1997; 238: 549-555. (Pubitemid 27464425)
9. Takayama TK, McMullen BA, Nelson PS, Matsumura M, Fujikawa K. Characterization of hK4 (prostase), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase. Biochemistry 2001; 40: 15341-15348. (Pubitemid 33151949)
10. Michael IP, Pampalakis G, Mikolajczyk SD, Malm J, Sotiropou-lou G, Diamandis EP. Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression. J Biol Chem 2006; 281: 12743-12750. (Pubitemid 43855365)
11. McCormack RT, Rittenhouse HG, Finlay JA, Sokoloff RL, Wang TJ, Wolfert RL et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology 1995; 45: 729-744.
12. 00 a molecular form of prostate-specific antigen that is associated with benign prostatic hyperplasia. Prostate 2000; 45: 271-276.
13. Mikolajczyk SD, Rittenhouse HG. Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer. Keio J Med 2003; 52: 86-91. (Pubitemid 36834402)
14. Niemelä P, L övgren J, Karp M, Lilja H, Pettersson K. Sensitive and specific enzymatic assay for the determination of precursor forms of prostate-specific antigen after an activation step. Clin Chem 2002; 48: 1257-1264. (Pubitemid 34809834)
15. Parwani AV, Marlow C, Demarzo AM, Mikolajczyk SD, Rittenhouse HG, Veltri RW et al. Immunohistochemical staining of precursor forms of prostate-specific antigen (proPSA) in metastatic prostate cancer. Am J Surg Pathol 2006; 30: 1231-1236. (Pubitemid 44454700)
16. Réhault S, Monget P, Mazerbourg S, Tremblay R, Gutman N, Gauthier F et al. Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3. Eur J Biochem 2001; 268: 2960-2968. (Pubitemid 32862980)
17. Cramer SD, Chen Z, Peehl DM. Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: Inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J Urol 1996; 156: 526-531. (Pubitemid 126445373)
18. Dallas SL, Zhao S, Cramer SD, Chen Z, Peehl DM, Bonewald LF. Preferential production of latent transforming growth factor beta-2 by primary prostatic epithelial cells and its activation by prostate-specific antigen. J Cell Physiol 2005; 202: 361-370. (Pubitemid 40041306)
19. Vukmirovic-Popovic S, Escott NG, Duivenvoorden WC. Presence and enzymatic activity of prostate-specific antigen in archival prostate cancer samples. Oncol Rep 2008; 20: 897-903.
20. Duivenvoorden WCM, Vukmirovic-Popovic S, Lhotak S, Seidlitz E, Hirte HW, Tozer RG et al. Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer. Cancer Res 2002; 62: 1588-1591. (Pubitemid 34408474)
21. Lhotak S, Elavathil LJ, Vukmirovic-Popovic S, Duivenvoorden WC, Tozer RG, Singh G. Immunolocalization of matrix metalloprotei-nases and their inhibitors in clinical specimens of bone metastasis from breast carcinoma. Clin Exp Metastasis 2001; 18: 463-470.
22. Lundwall A, Band V, Blaber M, Clements JA, Courty Y, Diamandis EP et al. A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol Chem 2006; 387: 637-641. (Pubitemid 43964785)
23. Ishii K, Otsuka T, Iguchi K, Usui S, Yamamoto H, Sugimura Y et al. Evidence that the prostate-specific antigen (PSA)/Zn(2+) axis may play a role in human prostate cancer cell invasion. Cancer Lett 2004; 207: 79-87. (Pubitemid 38429889)
24. Corey E, Brown LG, Corey MJ, Buhler KR, Vessella RL. LNCaP produces both putative zymogen and inactive, free form of prostate-specific antigen. Prostate 1998; 35: 135-143. (Pubitemid 28183296)
25. Denmeade SR, Sokoll LJ, Chan DW, Khan SR, Isaacs JT. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate 2001; 48: 1-6. (Pubitemid 32545071)
26. Veveris-Lowe TL, Lawrence MG, Collard RL, Bui L, Herington AC, Nicol DL et al. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocr Relat Cancer 2005; 12: 631-643. (Pubitemid 41482997)
27. Misra UK, Payne S, Pizzo SV. Ligation of prostate cancer cell surface GRP78 activates a proproliferative and antiapoptotic feedback loop: a role for secreted prostate-specific antigen. J Biol Chem 2011; 286: 1248-1259.
28. Nadiminty N, Lou W, Lee SO, Mehraein-Ghomi F, Kirk JS, Conroy JM et al. Prostate-specific antigen modulates genes involved in bone remodeling and induces osteoblast differentiation of human osteosarcoma cell line SaOS-2. Clin Cancer Res 2006; 12: 1420-1430.
29. Powell GJ, Southby J, Danks JA, Stillwell RG, Hayman JA, Henderson MA et al. Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res 1991; 51: 3059-3061.
30. Schmid C, Schlapfer I, Keller A, Waldvogel M, Froesch ER, Zapf J. Effects of insulin-like growth factor (IGF) binding proteins (BPs)-3 and-6 on DNA synthesis of rat osteoblasts: further evidence for a role of auto-/paracrine IGF I but not IGF II in stimulating osteoblast growth. Biochem Biophys Res Commun 1995; 212: 242-248.
31. Miyakoshi N, Richman C, Qin X, Baylink DJ, Mohan S. Effects of recombinant insulin-like growth factor-binding protein-4 on bone formation parameters in mice. Endocrinology 1999; 140: 5719-5728. (Pubitemid 30645361)
32. Minuto F, Palermo C, Arvigo M, Barreca AM. The IGF system and bone. J Endocrinol Invest 2005; 28 (8 Suppl): 8-10.
33. Pfeilschifter J, Seyedin SM, Mundy GR. Transforming growth factor beta inhibits bone resorption in fetal rat long bone cultures. J Clin Invest 1988; 82: 680-685.
34. Lu L, Yaszemski MJ, Mikos AG. TGF-beta1 release from biodegradable polymer microparticles: its effects on marrow stromal osteoblast function. J Bone Joint Surg Am 2001; 83A (Suppl 1 Pt 2): S82-S91.
35. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350: 1655-1664.
36. Blomme EAG, Dougherty KM, Pienta KJ, Capen CC, Rosol TJ, McCauley LK. Skeletal metastasis of prostate adenocarcinoma in rats: morphometric analysis and role of parathyroid hormone-related protein. Prostate 1999; 39: 187-197. (Pubitemid 29203406)
37. Urwin GH, Percival RC, Beneton MNC, Williams JL, Kanis JA. Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol 1985; 57: 721-723. (Pubitemid 16211558)
38. Leinonen J, Zhang WM, Stenman UH. Complex formation between PSA isoenzymes and protease inhibitors. J Urol 1996; 155: 1099-1103. (Pubitemid 26052723)